Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZANT Extension in Adolescents with RLS
NCT02633683Phase 4Unknown
- Sponsor
- XenoPort, Inc.
- Start
- Jan 2016
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gabapentin enacarbil in restless legs syndrome (RLS), sponsored by XenoPort, Inc.. Status: unknown.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT02633683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633683.